CYPHERPUNK TECHNOLOGIES INC. (CYPH) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$4.69M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$4.82M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.17M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$16.88M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$4.69M | (m) | (m) | (m) | (m) | -$2.69M* | (m) | $197.00K | (m) | $1.97M |
| 2026-03-31 | Reported | (m) | -$4.82M | (m) | (m) | (m) | (m) | -$3.43M | (m) | $161.00K | (m) | -$5.12M |
| 2025-09-30 | Reported | (m) | -$3.17M | (m) | (m) | (m) | (m) | -$8.32M* | (m) | $1.25M | (m) | $202.00K |
| 2025-06-30 | Reported | (m) | -$16.88M | (m) | (m) | (m) | (m) | -$14.49M* | (m) | $10.54M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$15.92M | (m) | (m) | (m) | (m) | -$14.48M | (m) | $12.91M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$17.86M | (m) | (m) | (m) | (m) | -$15.60M* | (m) | $14.91M | (m) | $708.00K |
| 2024-06-30 | Reported | (m) | -$21.25M | (m) | (m) | (m) | (m) | -$13.67M* | (m) | $17.89M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$14.82M | (m) | (m) | (m) | (m) | -$15.52M | (m) | $11.30M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$14.83M | (m) | (m) | (m) | (m) | -$10.49M* | (m) | $11.50M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$14.66M | (m) | (m) | (m) | (m) | -$10.19M* | (m) | $11.10M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$42.73M | (m) | (m) | (m) | (m) | -$12.70M | (m) | $38.94M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$15.29M | (m) | (m) | (m) | (m) | -$12.25M* | (m) | $12.10M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$16.90M | (m) | (m) | (m) | (m) | -$12.26M* | (m) | $14.04M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$10.63M | (m) | (m) | (m) | (m) | -$11.52M | (m) | $7.78M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$12.14M | (m) | $375.00K | (m) | (m) | -$8.10M* | (m) | $10.08M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$9.63M | (m) | $375.00K | (m) | (m) | -$7.75M* | (m) | $7.21M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$9.17M | (m) | $375.00K | (m) | (m) | -$8.59M | (m) | $6.81M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$7.51M | (m) | $375.00K | (m) | (m) | -$6.59M* | (m) | $5.37M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$7.50M | (m) | $375.00K | (m) | (m) | -$9.45M* | (m) | $5.35M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$6.38M | (m) | $375.00K | (m) | (m) | -$3.93M | (m) | $4.60M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$7.92M | (m) | (m) | (m) | $0.00* | -$6.96M* | (m) | $5.77M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$8.46M | (m) | (m) | (m) | (m) | -$7.18M* | (m) | $6.14M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$8.79M | (m) | (m) | (m) | (m) | -$6.87M | (m) | $6.79M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$8.60M | (m) | (m) | (m) | (m) | -$7.45M* | (m) | $6.46M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$6.84M | (m) | (m) | (m) | (m) | -$6.05M* | (m) | $4.23M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$6.34M | (m) | (m) | (m) | (m) | -$5.48M | (m) | $4.23M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$8.58M | (m) | (m) | (m) | -$2.00K* | -$2.36M* | (m) | $6.80M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$7.02M | (m) | (m) | (m) | $1.00K* | -$7.06M* | (m) | $4.88M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$10.21M | (m) | (m) | (m) | $65.00K | -$6.35M | (m) | $6.40M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$7.03M | (m) | (m) | (m) | $0.00* | -$7.37M* | (m) | $5.66M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$7.19M | (m) | (m) | (m) | $106.00K* | (m) | (m) | $6.12M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$5.14M | (m) | (m) | (m) | $30.00K | (m) | (m) | $4.09M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$41.07M | (m) | (m) | (m) | (m) | -$43.90M | (m) | $25.67M | (m) | $5.25M |
| 2024-12-31 | Reported | (m) | -$70.06M | (m) | (m) | (m) | (m) | -$60.30M | (m) | $57.21M | (m) | $585.00K |
| 2023-12-31 | Reported | (m) | -$87.04M | (m) | (m) | (m) | (m) | -$43.75M | (m) | $73.23M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$56.76M | (m) | (m) | (m) | (m) | -$49.04M | (m) | $44.97M | (m) | $147.00K |
| 2021-12-31 | Reported | (m) | -$41.43M | (m) | $1.50M | (m) | (m) | -$35.16M | (m) | $32.16M | (m) | -$24.00K |
| 2020-12-31 | Reported | (m) | -$28.54M | (m) | $1.50M | (m) | (m) | -$25.96M | (m) | $20.42M | (m) | -$2.00K |
| 2019-12-31 | Reported | (m) | -$33.45M | (m) | (m) | (m) | $100.00K | -$26.90M | (m) | $24.37M | (m) | -$3.00K |
| 2018-12-31 | Reported | (m) | -$30.75M | (m) | (m) | (m) | (m) | -$26.03M | (m) | $21.83M | (m) | $20.00K |
| 2017-12-31 | Reported | (m) | -$32.35M | (m) | (m) | (m) | $64.00K | -$22.14M | (m) | $22.50M | (m) | -$157.00K |
| 2016-12-31 | Reported | (m) | -$27.30M | (m) | (m) | (m) | $144.00K | -$25.34M | (m) | $23.29M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |